Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
JCI Insight (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
ACS Central Science (2023) Vol. 9, Iss. 8, pp. 1658-1669
Open Access | Times Cited: 204
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
Davide Marangoni, Roberta Maria Antonello, Marco Coppi, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 53-56
Open Access | Times Cited: 27
Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
Divya Teli, Pankti C. Balar, Kishan Patel, et al.
Metabolites (2023) Vol. 13, Iss. 2, pp. 309-309
Open Access | Times Cited: 25
Early combination therapy of COVID-19 in high-risk patients
Hans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.
Infection (2023) Vol. 52, Iss. 3, pp. 877-889
Open Access | Times Cited: 21
B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience
Alessandra D’Abramo, Serena Vita, Alessia Beccacece, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 10
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Emerging SARS-CoV-2 Resistance After Antiviral Treatment
Trevor J M Tamura, Manish C. Choudhary, Rinki Deo, et al.
JAMA Network Open (2024) Vol. 7, Iss. 9, pp. e2435431-e2435431
Open Access | Times Cited: 7
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Favipiravir and Ribavirin protect immunocompetent mice from lethal CCHFV infection
Thomas Tipih, Kimberly Meade‐White, Deepashri Rao, et al.
Antiviral Research (2023) Vol. 218, pp. 105703-105703
Open Access | Times Cited: 12
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
Hong‐Yi Zheng, Tian‐Zhang Song, Yong‐Tang Zheng
动物学研究 (2024) Vol. 45, Iss. 4, pp. 747-766
Open Access | Times Cited: 4
Aprotinin—Drug against Respiratory Diseases
Alexandre V. Ivachtchenko, A. V. Ivashchenko, Dmitrii O. Shkil, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11173-11173
Open Access | Times Cited: 10
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations
Shuntai Zhou, Nathan Long, Kyle Rosenke, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 6, pp. 1380-1383
Closed Access | Times Cited: 3
SARS-CoV-2 superinfection in CD14+ monocytes with latent human cytomegalovirus (HCMV) promotes inflammatory cascade
Shannon Harger Payen, Kabita Adhikari, Juli Petereit, et al.
Virus Research (2024) Vol. 345, pp. 199375-199375
Open Access | Times Cited: 2
Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression
Evelyn J. Franco, George L. Drusano, Kaley C. Hanrahan, et al.
Viruses (2023) Vol. 15, Iss. 5, pp. 1175-1175
Open Access | Times Cited: 7
Metabolomic Analysis and Antiviral Screening of a Marine Algae Library Yield Jobosic Acid (2,5-Dimethyltetradecanoic Acid) as a Selective Inhibitor of SARS-CoV-2
Marie L. Matos-Hernández, Robert M. Samples, Grayce Dyer, et al.
Journal of Natural Products (2024) Vol. 87, Iss. 6, pp. 1513-1520
Closed Access | Times Cited: 1
Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
Teena Bajaj, Eddie Wehri, Rahul K. Suryawanshi, et al.
RSC Advances (2023) Vol. 13, Iss. 26, pp. 17667-17677
Open Access | Times Cited: 4
Attention Mechanism-Based Graph Neural Network Model for Effective Activity Prediction of SARS-CoV-2 Main Protease Inhibitors: Application to Drug Repurposing as Potential COVID-19 Therapy
Yanling Wu, Kun Li, Menglong Li, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 22, pp. 7011-7031
Closed Access | Times Cited: 4
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
Henrik Berg Rasmussen, Peter Riis Hansen
Viruses (2023) Vol. 15, Iss. 11, pp. 2151-2151
Open Access | Times Cited: 3
Early combination therapy of COVID-19 in high-risk patients
Hans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Concomitant and sequential administration of nirmatrelvir‐ritonavir and azvudine in patients with COVID‐19 caused by the Omicron variant: Safety and efficacy
G Chen, You‐Rou Zheng, Yun‐Ni Yu, et al.
iLABMED (2024) Vol. 2, Iss. 2, pp. 88-97
Open Access
Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm
Daniel R. Kuritzkes
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 6, pp. 1297-1298
Closed Access
Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA
A Sakai, Gagandeep Singh, Mahsa Khoshbakht, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 4, pp. 102331-102331
Open Access
Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia
Denise Siegrist, Hulda R. Jónsdóttir, Mendy Bouveret, et al.
Pharmaceutics (2024) Vol. 16, Iss. 10, pp. 1262-1262
Open Access
N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses
Durbadal Ojha, Collin S Hill, Shuntai Zhou, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 9, pp. e1012574-e1012574
Open Access
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo
Hin Chu, Huiping Shuai, Jingxin Qiao, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top